SCHEMBL2120261

SCHEMBL2120261

Cc1ccc(-n2cccc2)cc1NS(=O)(=O)c1ccc(N)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.52
MEN1 O00255 5/20 0.52
POLB P06746 1/20 0.52
HSD17B10 Q99714 1/20 0.52
GHSR Q92847 3/20 0.46
TERT O14746 1/20 0.46
ALDH1A1 P00352 6/20 0.46
MAPT P10636 4/20 0.46
PKM P14618 3/20 0.46
TDP1 Q9NUW8 2/20 0.46
KDM4E B2RXH2 1/20 0.46
BLM P54132 1/20 0.46
HPGD P15428 2/20 0.46
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA9 Q16790 1/20 0.45
CYP3A4 P08684 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
LMNA P02545 2/20 0.44
HTR6 P50406 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2118542 0.87 MEN1 (0.52) KMT2AMEN1POLBHSD17B10GHSR
SCHEMBL2120628 0.87 ALDH1A1 (0.59) KMT2AMEN1POLBHSD17B10GHSR
SCHEMBL2118361 0.85 GHSR (0.45) KMT2AMEN1POLBGHSRTERT
SCHEMBL2119976 0.81 KMT2A (0.45) KMT2AMEN1POLBHSD17B10GHSR
SCHEMBL2119501 0.81 KMT2A (0.48) KMT2AMEN1POLBHSD17B10GHSR
SCHEMBL2119724 0.80 TERT (0.51) KMT2AMEN1POLBHSD17B10GHSR
SCHEMBL2117278 0.80 KMT2A (0.46) KMT2AMEN1POLBHSD17B10GHSR
SCHEMBL2121533 0.78 MEN1 (0.45) KMT2AMEN1POLBHSD17B10GHSR
SCHEMBL2119327 0.77 MEN1 (0.46) KMT2AMEN1POLBHSD17B10GHSR
SCHEMBL18757864 0.76 KEAP1 (0.56) KMT2APOLBHSD17B10ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1AN, HIF1A, EGLN2 KMT2A 276/4885MEN1 3114/4885POLB 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.